Lutrate (leuprorelin): Reviews and patient testimonials
Back to the list of medications
Medication indications
Lutrate 1 month Depot 3.75 mg powder and solvent for prolonged-release suspension for injection
(i) Metastatic prostate cancer.
(ii) Locally advanced prostate cancer, as an alternative to surgical castration.
(iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
(iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
(v) As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
Lutrate 3 month Depot 22.5 mg powder and solvent for prolonged-release suspension for injection
(i) Metastatic prostate cancer.
(ii) Locally advanced prostate cancer, as an alternative to surgical castration.
(iii) As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
(iv) As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
(v) As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
Route of administration: Injectable
Molecule: leuprorelin
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.